array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(25) "Gsk Consumer Health, Inc."
["slug"]=>
string(32) "4abba-us-gsk-consumer-health-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/8434ac9a-9bf2-4877-a3a0-a4039c237204"
["description"]=>
string(518) "GSK Consumer Healthcare is a global business that discovers, develops, and manufactures innovative consumer healthcare products. It is an associate of GlaxoSmithKline plc, one of the world's largest healthcare companies. GSK Consumer Healthcare aims to become one of the world's most innovative, best performing, and trusted healthcare companies. Their goal is to improve lives through scientific innovation, build category-defining brands, and become Pakistan's first and best Fast Moving Consumer Healthcare Company."
["address_street"]=>
string(28) "184 Liberty Corner Rd Ste 78"
["address_place"]=>
string(6) "Warren"
["address_region"]=>
string(10) "New Jersey"
["founding_date"]=>
string(10) "1994-02-28"
["website_domain"]=>
string(7) "gsk.com"
["website_url"]=>
string(19) "https://www.gsk.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(300)
["article_count"]=>
int(450)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(58) "Pfizer Plans to Sell About £2 Billion of Shares in Haleon"
["snippet_en"]=>
string(302) "(Bloomberg) -- Pfizer Inc. plans to sell about £2 billion ($2.5 billion) of shares in Haleon Plc, the first step by the UK consumer health company’s biggest shareholder to reduce its 32% stake. Most Read from BloombergApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesPutin Warns Russia"
["url"]=>
string(76) "https://uk.finance.yahoo.com/news/pfizer-plans-sell-2-billion-091752678.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/aca5122a-c2fc-4be4-89d1-00df1a0ded87"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(5) {
[0]=>
string(14) "Issuing Shares"
[1]=>
string(18) "Activist Investors"
[2]=>
string(16) "Share Repurchase"
[3]=>
string(18) "General Investment"
[4]=>
string(11) "Acquisition"
}
}
[1]=>
array(7) {
["title_en"]=>
string(127) "Major Pharmaceutical Companies Adapt to Changing Consumer Health Market through Divestments and Strategic Shifts - News Biggest"
["snippet_en"]=>
string(156) "Pfizer is selling approximately 630 million shares of Haleon, which will lower its stake in the company from 32% to around 24%. This transaction is expected"
["url"]=>
string(137) "https://newsbiggest.com/major-pharmaceutical-companies-adapt-to-changing-consumer-health-market-through-divestments-and-strategic-shifts/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/eb0e8b0b-fd0c-42b6-abb5-5655bb4dc43a"
["source"]=>
string(15) "newsbiggest.com"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(6) {
[0]=>
string(8) "spin-off"
[1]=>
string(18) "General Investment"
[2]=>
string(12) "Stock Market"
[3]=>
string(25) "Business Model Resilience"
[4]=>
string(24) "Stock Research & Ratings"
[5]=>
string(11) "Acquisition"
}
}
[2]=>
array(7) {
["title_en"]=>
string(58) "Pfizer to sell partial stake in Haleon for more than £2bn"
["snippet_en"]=>
string(135) "The pharmaceutical group plans to lower its holding in Haleon, which also makes Panadol painkillers and Nicorette gum, from 32% to 24%."
["url"]=>
string(82) "https://whatsnew2day.com/pfizer-to-sell-partial-stake-in-haleon-for-more-than-2bn/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f703f8c0-3241-4452-b366-ead36ffd104c"
["source"]=>
string(16) "whatsnew2day.com"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(5) {
[0]=>
string(13) "Collaboration"
[1]=>
string(10) "Divestment"
[2]=>
string(18) "General Investment"
[3]=>
string(12) "Stock Market"
[4]=>
string(11) "Acquisition"
}
}
[3]=>
array(7) {
["title_en"]=>
string(79) "FTSE 100 Live: Blue chips higher, Currys ups guidance, Pfizer sells down Haleon"
["snippet_en"]=>
string(150) "FTSE 100 9 points higher at 7,736 Currys ups profit guidance Pfizer sells down Haleon stake 9:57am: World's largest solar panel manufacturer to cut..."
["url"]=>
string(145) "https://proactiveinvestors.co.uk/companies/news/1043333/ftse-100-live-blue-chips-higher-currys-ups-guidance-pfizer-sells-down-haleon-1043333.html"
["image_url"]=>
NULL
["source"]=>
string(24) "proactiveinvestors.co.uk"
["publication_date"]=>
string(10) "2024-03-18"
["categories"]=>
array(7) {
[0]=>
string(13) "Collaboration"
[1]=>
string(18) "General Investment"
[2]=>
string(12) "Stock Market"
[3]=>
string(31) "Financial Update/Profit Warning"
[4]=>
string(8) "Downtime"
[5]=>
string(19) "Green & Responsible"
[6]=>
string(11) "Acquisition"
}
}
[4]=>
array(7) {
["title_en"]=>
string(57) "Nocion, chasing GSK, pulls in $62M for chronic cough drug"
["snippet_en"]=>
string(146) "Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal."
["url"]=>
string(74) "https://finance.yahoo.com/news/nocion-chasing-gsk-pulls-62m-141800570.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/190ce258-2ff3-447b-a7aa-27693eb6d8c8"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2024-03-04"
["categories"]=>
array(1) {
[0]=>
string(11) "Acquisition"
}
}
[5]=>
array(7) {
["title_en"]=>
string(69) "GSK acquires the rights to a cancer drug candidate from Hansoh Pharma"
["snippet_en"]=>
string(161) "GlaxoSmithKline has strengthened its portfolio of oncology products by acquiring the Chinese group Hansoh Pharmaceutical the exclusive rights to a promising cand"
["url"]=>
string(111) "https://saludnews.net/gsk-se-hace-con-los-derechos-de-un-candidato-a-farmaco-contra-el-cancer-de-hansoh-pharma/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/25f32e8c-cc0b-4ddc-a79d-9ed5f6f39532"
["source"]=>
string(13) "saludnews.net"
["publication_date"]=>
string(10) "2024-01-02"
["categories"]=>
array(3) {
[0]=>
string(26) "Product Quality and safety"
[1]=>
string(36) "Human Rights and Community Relations"
[2]=>
string(11) "Acquisition"
}
}
[6]=>
array(7) {
["title_en"]=>
string(35) "GSK further reduces stake in Haleon"
["snippet_en"]=>
string(183) "DJ GSK further reduces stake in Haleon By Christian Moess Laursen FRANKFURT (Dow Jones)--The British pharmaceutical company GSK wants to sell 270 million shares in Haleon and thus its"
["url"]=>
string(112) "https://www.finanznachrichten.de/nachrichten-2023-10/60295550-gsk-reduziert-beteiligung-an-haleon-weiter-015.htm"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/24cb7dff-3f13-4674-b0f5-6b73ca7d715c"
["source"]=>
string(20) "finanznachrichten.de"
["publication_date"]=>
string(10) "2023-10-05"
["categories"]=>
array(1) {
[0]=>
string(11) "Acquisition"
}
}
[7]=>
array(7) {
["title_en"]=>
string(37) "Luther partner moves to GSK Stockmann"
["snippet_en"]=>
string(153) "GSK Stockmann strengthens itself with Anna Gassner. The lawyer advises in the areas of corporate M&A and private equity and previously worked for Luther."
["url"]=>
string(110) "https://www.lto.de/recht/kanzleien-unternehmen/k/gsk-stockmann-zugang-equity-partnerin-luxemburg-anna-gassner/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/33a0fcec-5b18-4218-ad6f-04d955c74ad1"
["source"]=>
string(6) "lto.de"
["publication_date"]=>
string(10) "2023-10-02"
["categories"]=>
array(3) {
[0]=>
string(6) "Merger"
[1]=>
string(10) "Relocation"
[2]=>
string(11) "Acquisition"
}
}
[8]=>
array(7) {
["title_en"]=>
string(28) "GSK's Rukobia joins COMPR.AR"
["snippet_en"]=>
string(179) "At the beginning of August, the National Ministry of Health opened a Direct Exclusive Contract focused on the purchase of the antiretroviral Rukobia, from the British company GSK."
["url"]=>
string(61) "https://www.pharmabiz.net/rukobia-de-gsk-se-sube-al-compr-ar/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/18aede49-b6f8-471f-97b2-9f310ca508df"
["source"]=>
string(13) "pharmabiz.net"
["publication_date"]=>
string(10) "2023-08-02"
["categories"]=>
array(1) {
[0]=>
string(11) "Acquisition"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(28)
}
[1]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(26)
}
[2]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(26)
}
[3]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(21)
}
[4]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(20)
}
[5]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(18)
}
[6]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(17)
}
[7]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(16)
}
[8]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(15)
}
[9]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(14)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(14)
}
[11]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(13)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(12)
}
[13]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(11)
}
[14]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(10)
}
[15]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(10)
}
[16]=>
array(2) {
["name"]=>
string(20) "Business Development"
["count"]=>
int(9)
}
[17]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(9)
}
[18]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(8)
}
[19]=>
array(2) {
["name"]=>
string(16) "Customer Welfare"
["count"]=>
int(7)
}
[20]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(7)
}
[21]=>
array(2) {
["name"]=>
string(19) "Economic Conditions"
["count"]=>
int(6)
}
[22]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(6)
}
[23]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(6)
}
[24]=>
array(2) {
["name"]=>
string(6) "Crisis"
["count"]=>
int(6)
}
[25]=>
array(2) {
["name"]=>
string(21) "Cultural developments"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(6)
}
[27]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(6)
}
[28]=>
array(2) {
["name"]=>
string(24) "Employee Health & Safety"
["count"]=>
int(6)
}
[29]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(5)
}
}
}
4abba-us-gsk-consumer-health-inc
Gsk Consumer Health, Inc.
Location
New Jersey
Founded
1994-02-28
Website
https://www.gsk.com
Articles
450 Articles
Category
Pharmaceutical Preparations
Description
GSK Consumer Healthcare is a global business that discovers, develops, and manufactures innovative consumer healthcare products. It is an associate of GlaxoSmithKline plc, one of the world's largest healthcare companies. GSK Consumer Healthcare aims to become one of the world's most innovative, best performing, and trusted healthcare companies. Their goal is to improve lives through scientific innovation, build category-defining brands, and become Pakistan's first and best Fast Moving Consumer Healthcare Company.
(Bloomberg) -- Pfizer Inc. plans to sell about £2 billion ($2.5 billion) of shares in Haleon Plc, the first step by the UK consumer health company’s biggest shareholder to reduce its 32% stake. Most Read from BloombergApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesPutin Warns Russia
Pfizer is selling approximately 630 million shares of Haleon, which will lower its stake in the company from 32% to around 24%. This transaction is expected
GlaxoSmithKline has strengthened its portfolio of oncology products by acquiring the Chinese group Hansoh Pharmaceutical the exclusive rights to a promising cand
DJ GSK further reduces stake in Haleon By Christian Moess Laursen FRANKFURT (Dow Jones)--The British pharmaceutical company GSK wants to sell 270 million shares in Haleon and thus its
GSK Stockmann strengthens itself with Anna Gassner. The lawyer advises in the areas of corporate M&A and private equity and previously worked for Luther.
At the beginning of August, the National Ministry of Health opened a Direct Exclusive Contract focused on the purchase of the antiretroviral Rukobia, from the British company GSK.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.